WO2008124858A3 - Targeted receptor - Google Patents

Targeted receptor Download PDF

Info

Publication number
WO2008124858A3
WO2008124858A3 PCT/AT2008/000132 AT2008000132W WO2008124858A3 WO 2008124858 A3 WO2008124858 A3 WO 2008124858A3 AT 2008000132 W AT2008000132 W AT 2008000132W WO 2008124858 A3 WO2008124858 A3 WO 2008124858A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeted receptor
methods
targeted
receptor
receptor molecule
Prior art date
Application number
PCT/AT2008/000132
Other languages
French (fr)
Other versions
WO2008124858A2 (en
Inventor
Gottfried Himmler
Gerda Redl
Geert Mudde
Original Assignee
F Star Biotech Forsch & Entw
Gottfried Himmler
Gerda Redl
Geert Mudde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Biotech Forsch & Entw, Gottfried Himmler, Gerda Redl, Geert Mudde filed Critical F Star Biotech Forsch & Entw
Publication of WO2008124858A2 publication Critical patent/WO2008124858A2/en
Publication of WO2008124858A3 publication Critical patent/WO2008124858A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Abstract

Targeted receptor molecule based on a receptor of soluble inflammatory antigens, binding specifically to a membrane bound marker of inflammation, methods of producing said targeted receptor molecule and methods of anti-inflammatory treatment.
PCT/AT2008/000132 2007-04-11 2008-04-11 Targeted receptor WO2008124858A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91120407P 2007-04-11 2007-04-11
US60/911,204 2007-04-11

Publications (2)

Publication Number Publication Date
WO2008124858A2 WO2008124858A2 (en) 2008-10-23
WO2008124858A3 true WO2008124858A3 (en) 2008-12-11

Family

ID=39731161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2008/000132 WO2008124858A2 (en) 2007-04-11 2008-04-11 Targeted receptor

Country Status (1)

Country Link
WO (1) WO2008124858A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
JP2012532838A (en) * 2009-07-09 2012-12-20 エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Stabilized immunoglobulin constant domains
JP5673992B2 (en) * 2009-10-30 2015-02-18 国立大学法人東京農工大学 Vascular endothelial growth factor binding aptamer
PL2566517T3 (en) 2010-05-04 2019-04-30 Five Prime Therapeutics Inc Antibodies that bind csf1r
CN105585630B (en) 2010-07-29 2020-09-15 Xencor公司 Antibodies with modified isoelectric points
EP2546268A1 (en) * 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
RU2718751C2 (en) 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Methods of treating pathological conditions with antibodies which bind to the colony-stimulating factor 1 receptor (csf1r)
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
LT2943511T (en) 2013-01-14 2019-11-11 Xencor Inc Novel heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
UA119167C2 (en) 2014-03-28 2019-05-10 Зенкор, Інк. Bispecific antibodies that bind to cd38 and cd3
SG10201811475YA (en) 2014-06-23 2019-02-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
MX2016017393A (en) 2014-07-01 2017-09-05 Pfizer Bispecific heterodimeric diabodies and uses thereof.
DK3212670T3 (en) 2014-10-29 2021-03-22 Five Prime Therapeutics Inc COMBINATION THERAPY AGAINST CANCER
IL252480B2 (en) 2014-11-26 2023-12-01 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
BR112017013111A2 (en) 2014-12-22 2018-05-15 Five Prime Therapeutics Inc methods of treating a disorder and treating synovitis, use of an antibody and antibody
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN107709365A (en) 2015-04-13 2018-02-16 戊瑞治疗有限公司 Cancer combination treatment
KR20180023892A (en) 2015-04-17 2018-03-07 암젠 리서치 (뮌헨) 게엠베하 The bispecific antibody constructs for CDH3 and CD3
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
MA45255A (en) 2016-06-14 2019-04-17 Xencor Inc BISPECIFIC CONTROL POINT INHIBITORS ANTIBODIES
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
EP3596108A4 (en) * 2017-03-15 2020-12-23 Pandion Operations, Inc. Targeted immunotolerance
JP2020521452A (en) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド Targeted tolerance
CA3067603A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
EP3681535A1 (en) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
KR20210069641A (en) 2018-10-03 2021-06-11 젠코어 인코포레이티드 IL-12 heterodimeric Fc-fusion protein
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. Madcam targeted immunotolerance
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc Anti-cd28 compositions
JP2024511319A (en) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and CLDN6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
WO2006072620A1 (en) * 2005-01-05 2006-07-13 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
WO2006072620A1 (en) * 2005-01-05 2006-07-13 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OWENS R ET AL: "The in vivo and in vitro characterisation of an engineered human antibody to E-selectin", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 2, 1 June 1997 (1997-06-01), pages 107 - 116, XP004126673, ISSN: 1380-2933 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens

Also Published As

Publication number Publication date
WO2008124858A2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
WO2008124858A3 (en) Targeted receptor
WO2008021156A3 (en) Antibodies to il-17a
WO2008157356A3 (en) Antibody formulations
WO2008047134A3 (en) Antibody molecules which bind il-17a and il-17f
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2010145792A8 (en) Bispecific antigen binding proteins
WO2011005023A3 (en) Semiconductor nanocrystal and preparation method thereof
MX314208B (en) Adhesion and cohesion modifiers for asphalt.
WO2008147196A3 (en) Rsv-specific binding molecules and means for producing them
EP3199551A3 (en) Fully human antibodies to btla
WO2008134668A3 (en) Heat-labile prodrugs
WO2007106744A8 (en) Anti-5t4 antibodies and uses thereof
NO20092652L (en) Constructed anti-TSLP antibody
WO2011110642A3 (en) Monoclonal antibodies against c-met
WO2009058492A3 (en) Fc variants with altered binding to fcrn
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
JP2009256388A5 (en)
WO2009020933A3 (en) Therapeutic use of anti-tweak receptor antibodies
WO2010003101A3 (en) Il6 immunotherapeutics
WO2010045598A3 (en) Psma binding ligand-linker conjugates and methods for using
WO2009039307A3 (en) Hydrogels and methods for producing and using the same
GT200500385A (en) TRICYCLE AMINOALCOHOLES, PROCEDURES FOR PREPARATION AND USE AS INFLAMMATION INHIBITORS
BRPI0907537A2 (en) Turbocharger Paddle Wheel, Turbocharger Distributor Sector, Turbocharger Paddle Wheel
WO2011009539A8 (en) ε-POLYLYSINE CONJUGATES AND USE THEREOF
WO2009052125A9 (en) Human anti-amyloid antibodies, compositions, methods and uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08733235

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08733235

Country of ref document: EP

Kind code of ref document: A2